GIIGAS: Grupo de Investigación en Interacción Gen-Ambiente-Salud, Dpt of Biomedical Sciences, Area of Preventive Medicine and Public Health, Instituto de Biomedicina (IBIOMED), University of León, Leon, Spain.
CIBERESP, CIBER de Epidemiología y Salud Pública, Madrid, Spain.
Sci Rep. 2017 Oct 23;7(1):13806. doi: 10.1038/s41598-017-13670-z.
Enhancer of zeste homolog 2 (EZH2) is the catalitic subunit of polycomb repressive complex 2 and mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis. The role of the gene EZH2 in colorectal cancer survival is uncertainly, the aim of this study is clear this relationship. Relevant literaure was searched from electronic databases. A meta-analysis was performed with elegible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with colorectal cancer. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 8 studies (n = 1059 patients) that evaluated the correlation between EZH2 overexpression and survival in patients with colorectal cancer. Combined hazard ratios suggested that EZH2 overexpression was associated with better prognosis of overall survival (OS) HR(hazard ratio) = 0.61 95% CI (0.38-0.84) We performed bias analysis according Egger and Begg,s test and we did not find publication bias. EZH2 overexpression indicates a better prognosis for colorectal cancer.
增强子结合锌指蛋白 2(EZH2)是多梳抑制复合物 2 的催化亚基,介导基因沉默。EZH2 在许多癌症中过表达,并与预后不良相关。EZH2 基因在结直肠癌生存中的作用尚不确定,本研究旨在明确这种关系。从电子数据库中检索相关文献。对定量评估 EZH2 过表达与结直肠癌患者生存关系的合格研究进行荟萃分析。汇总并定量分析生存数据。我们对 8 项研究(n=1059 例患者)进行了荟萃分析,评估了 EZH2 过表达与结直肠癌患者生存的相关性。合并风险比表明,EZH2 过表达与总生存(OS)的预后较好相关(HR=0.61,95%CI:0.38-0.84)。我们根据 Egger 和 Begg 的检验进行了偏倚分析,并未发现发表偏倚。EZH2 过表达提示结直肠癌预后较好。